HARBIN, China, May 7 /Xinhua-PRNewswire-FirstCall/ -- Renhuang Pharmaceuticals, Inc. (Pink Sheets: RHGP) (“Renhuang” or “the Company”), a leading pharmaceutical company in the People’s Republic of China (“PRC”), today announced its successful participation in the 59th PharmChina Fair, hosted in Xian, China from April 15th to April 17th, 2008.
PharmChina Fair has more than 30 years of history and is the largest and most well respected trade show in the Chinese pharmaceutical industry. Held twice a year, it attracts manufacturers, distributors, agencies, researchers and industry experts from around the country. About 2,000 pharmaceutical representatives and more than 100,000 purchasers attended the event this year.
Renhuang presented its leading branded drug, Acanthopanax (Siberian Ginseng), at the trade show. Acanthopanax, extracted from natural plants for the treatment of sleep disorders and depression by easing the nerves, was highly popular with the distributors and visitors. Acanthopanax is one of the preferred TCM treatments for depression, as it has no side effects. The Company signed two letters of intent for distribution collaborations at the event.
“We intend to continue our strategy of increasing our presence at trade shows and exhibitions to promote our products and improve brand name recognition. Additionally, we will continue to provide the most innovative products to meet the demands of the Chinese pharmaceutical market,” said Mr. Shao-ming Li, Chairman and CEO of Renhaung Pharmaceuticals, Inc.
About Renhuang Pharmaceuticals, Inc.
Founded in 1996, Renhuang Pharmaceuticals, Inc, produces western, traditional Chinese medicines (TCM), and branded pharmaceuticals, using its GMP-certified facilities in China. The Company’s GMP-certified manufacturing facilities, containing cutting-edge technologies and advance equipment, are capable of producing as many as 200 types of pharmaceuticals. Additionally, Renhuang distributes raw materials and finished pharmaceutical products using its extensive distribution channels and third party distributors throughout China. The Company’s distribution network includes over 3,000 sales representatives in 70 sales centers across 24 districts, covering over 50% of the greater China. The Company also exports its products to Russia and Southeast Asia. For more information, visit http://www.renhuang.com .
Safe Harbor Statement
Certain of the statements made in the press release constitute
forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by the use of forward- looking terminology such as "believe," "expect," "may," "will," "should," "project," "plan," "seek," "intend," or "anticipate" or the negative thereof or comparable terminology. Such statements typically involve risks and uncertainties and may include financial projections or information regarding our future plans, objectives or performance. Actual results could differ materially from the expectations reflected in such forward-looking statements as a result of a variety of factors, including the risks associated with the effect of changing economic conditions in The People’s Republic of China, variations in cash flow, reliance on collaborative retail partners and on new product development, variations in new product development, risks associated with rapid technological change, and the potential of introduced or undetected flaws and defects in products, and other risk factors detailed in reports filed with the Securities and Exchange Commission from time to time.
For more information, please contact:
Renhuang Pharmaceuticals, Inc.
Ms. Shuang Tan, IR Contact
Tel: +86-451-5392-5461
Email: ir@renhuang.com
CCG Elite Investor Relations Inc.
Mr. Crocker Coulson, President
Tel: +1-646-213-1915 (New York)
Email: crocker.coulson@ccgir.com
Web: http://www.ccgelite.com
